External control arm analysis: an evaluation of propensity score approaches, G-computation, and doubly debiased machine learning

Table 1 Description of the five type 2 diabetes clinical trials used for the internal replication study. We report only the trial-specific inclusion criteria

Trial	Nb. patients	Inclusion criteria	Arms	Background therapy
NCT01106625 [39]	469		Canagliflozin 300	Metformin and Sulphonylurea
			Sitaglipin 100
NCT01137812 [40]	755		Canagliflozin 300	Metformin and Sulphonylurea
			Canaglifozin 100
			Placebo
NTC01106651 [41]	659	Age: 55 to 80 y.o.	Canagliflozin 300	Metformin and
			Canaglifozin 100	Sulphonylurea (357 patients)
			Placebo	Metformin (302 patients)
NCT01106677 [42]	1284		Canagliflozin 300	Metformin
			Canaglifozin 100
			Sitaglipin 100
			Placebo
NCT00968812 [43]	1450	45\(\ge\)BMI\(\ge\)22	Canagliflozin 300	Metformin
			Canaglifozin 100
			Glimepiride 100

ISSN: 1471-2288